panadiplon

The damage hit without warning. Of the 40 healthy volunteers who had enrolled in a Phase I trial for panadiplon, an experimental… (More)

Adverse drug reactions appear during the clinical use of a drug and constitute a health problem, as they are an important cause… (More)

Ethanol's ability to enhance GABA neurotransmission via GABA(A) receptors has been implicated as an important mechanism… (More)

5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5] imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide) (RWJ-51204… (More)

Preclinical drug safety evaluation studies, typically conducted in two or more animal species, reveal and define dose-dependent… (More)

The pentobarbital-like discriminative stimulus effects of the benzodiazepine receptor partial agonist panadiplon were assessed in… (More)

Purpose. To develop an integrated absorption model for estimating the fraction of dose absorbed and determining the causes of… (More)

The quinoxalinone anxiolytic, panadiplon, was dropped from clinical development due to unexpected hepatic toxicity in human… (More)

The quinoxalinone anxiolytic, panadiplon, produces hepatic metabolic inhibition (mitochondrial impairment), microvesicular… (More)

The non-benzodiazepine anxiolytic, panadiplon, was discontinued from clinical development due to evidence of hepatic toxicity in… (More)